Blood spot test extended as of 1 January 2017 to include two more disorders As of 1 January 2017, the disorders alpha and beta thalassaemia will be added to the neonatal blood spot (‘heel prick’) screening programme.
Guus Velders in Nature's "Ten people that mattered this year" Researcher Dr Guus Velders of RIVM has made the Nature top-10 list of 2016. This means that, according to Nature, he was one of the 10 most influential scientists in 2016.
Playing sports on synthetic turf fields with rubber granulate is safe New research by the Dutch National Institute for Public Health and the Environment (RIVM) shows it is safe for people to play sports on synthetic turf fields with an infill of rubber granulate.
New version ReCiPe 2016 to determine environmental impact RIVM presents ReCiPe 2016 a new version of the in Europe commonly used life cycle impact model ReCiPe.
Slight increase in number of TB patients in 2015 After many years of decrease, the number of tuberculosis patients in the Netherlands rose again in 2015 by 6 percent.
No scientific evidence for effect front-of-pack labels Front-of-pack (FOP) nutrition labels can inform consumers about healthier products.
Leptospirosis cases continue to rise In 2015, the previously reported increase in the number of people with leptospirosis (Weil’s disease being its most common form) is continuing.
Mental care still the most expensive of all In 2011, 19.6 billion euros was spent on the treatment of mental disorders. This amounted to 22% of the total expenditure on health and welfare during that year.
Risks of eHealth technology RIVM and Nictiz have made an overview of the risks that eHealth applications may entail and how these risks can be controlled.
Key organisations unite to improve benefit and risk assessments of vaccines Leading organisations have joined forces to launch a unique project that will pave the way for a pan-European framework for rapidly assessing and communicating the benefits and risks of vaccines.